Publications

Export 35 results:
Author [ Title(Desc)] Type Year
Filters: Author is John CS Breitner  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Picard C, Julien C, Frappier J, Miron J, Théroux L, Dea D, Breitner JCS, Poirier J.  2018.  Alterations in cholesterol metabolism-related genes in sporadic Alzheimer's disease.. Neurobiol Aging. 66:180.e1-180.e9.
Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, Brockschnieder D, Dyrks T, Althoff V, Fraser PE et al..  2015.  Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.. J Alzheimers Dis. 44(2):613-24.
Leoutsakos J-M, Gross AL, Jones RN, Albert MS, Breitner JCS.  2016.  'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials.. J Prev Alzheimers Dis. 3(4):229-235.
Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner JCS, Dea D.  2014.  Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.. Neurobiol Aging. 35 Suppl 2:S3-10.
B
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
Vogel JW, Vachon-Presseau E, Binette APichet, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P et al..  2018.  Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.. Brain. 141(6):1871-1883.
C
Breitner JCS.  2017.  Comment: MCI trials-Categorical "square pegs" in dimensional "round holes"? Neurology. 88(18):1757.
Breitner JCS.  2015.  Comment: Yet another "disconnect" between amyloid and Alzheimer disease? Neurology. 85(8):698.
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2015.  Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.. Front Aging Neurosci. 7:242.
D
Tam A, Dansereau C, Badhwar AP, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P et al..  2016.  A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment.. Data Brief. 9:1122-1129.
Tuwaig M, Savard M, Jutras B, Poirier J, D Collins L, Rosa-Neto P, Fontaine D, Breitner JCS.  2017.  Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.. J Alzheimers Dis. 60(4):1589-1600.
Krysinska K, Sachdev PS, Breitner JCS, Kivipelto M, Kukull W, Brodaty H.  2017.  Dementia registries around the globe and their applications: A systematic review.. Alzheimers Dement.
Maysinger D, Ji J, Moquin A, Hossain S, Hancock MA, Zhang I, K Y Chang P, Rigby M, Anthonisen M, Grütter P et al..  2017.  Dendritic Polyglycerol Sulfates in the Prevention of Synaptic Loss and Mechanism of Action on Glia.. ACS Chem Neurosci.
H
Konishi K, Joober R, Poirier J, MacDonald K, M Chakravarty M, Patel R, Breitner JCS, Bohbot VD.  2018.  Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.. J Alzheimers Dis. 61(4):1493-1507.
Luck T, Riedel-Heller SG, Luppa M, Wiese B, Bachmann C, Jessen F, Bickel H, Weyerer S, Pentzek M, König H-H et al..  2014.  A hierarchy of predictors for dementia-free survival in old-age: results of the AgeCoDe study.. Acta Psychiatr Scand. 129(1):63-72.
I
Cavanagh C, Tse YChung, Nguyen H-B, Krantic S, Breitner JCS, Quirion R, Wong TPan.  2016.  Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model.. Neurobiol Aging. 47:41-49.
M
Chuang Y-F, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JCS, Ferruci L, Resnick SM, Thambisetty M.  2015.  Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.. Mol Psychiatry.
Breitner JCS.  2014.  Mild cognitive impairment and progression to dementia: new findings.. Neurology. 82(4):e34-5.
N
Heneka MT, Carson MJ, Khoury JEl, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM et al..  2015.  Neuroinflammation in Alzheimer's disease.. Lancet Neurol. 14(4):388-405.
O
Breitner JCS.  2015.  Observations on DSM-5 Mild Neurocognitive Disorder vs. its predecessor, Mild Cognitive Impairment.. Acta Psychiatr Scand. 131(1):15-7.
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
Zuo X-N, Anderson JS, Bellec P, Birn RM, Biswal BB, Blautzik J, Breitner JCS, Buckner RL, Calhoun VD, F Castellanos X et al..  2014.  An open science resource for establishing reliability and reproducibility in functional connectomics.. Sci Data. 1:140049.
P
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
R
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.  2016.  Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).. J Prev Alzheimers Dis. 3(4):236-242.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, M Chakravarty M.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.

Pages

  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre